Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Somewhat Bullish +50

Moderna looks to a subcutaneous Keytruda combo | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

📅 Moderna is initiating Interpath-014, a new clinical study combining its neoantigen immunotherapy inthesmeran autogene with subcutaneous Keytruda for adjuvant NSCLC treatment.

🔬 The study will enroll patients with early-stage I disease, distinguishing it from other ongoing trials that target later-stage stages or non-responders to prior therapy.

🧪 Unlike previous phase 3s using intravenous Keytruda, Interpath-014 will specifically evaluate a subcutaneous formulation of the PD-L1 inhibitor alongside inthesmeran autogene.

💉 Researchers are comparing two treatment arms: receiving inthesmeran with or without Keytruda versus placebo, rather than comparing to Keytruda alone as seen in other trials.

🗓️ The Interpath-014 trial is scheduled to begin recruitment in May this year, marking another expansion for Moderna's pipeline outside of its flagship melanoma research.

⏳ A major readout for the company's primary partnership with Merck & Co awaits from the Interpath-001 trial in adjuvant melanoma later this decade.

📊 Results for the melanoma-focused Interpath-001 are anticipated in 2026, representing a critical performance benchmark for Moderna/Merck collaborations.

📈 Moderna's stock price has recently risen following market anticipation of positive outcomes from its pending phase 3 data releases.

⚠️ The company issued a statement cautioning investors that the melanoma trial readout timing may be delayed slightly beyond initial expectations, potentially extending into 2026.

🤝 This new subcutaneous study represents a significant branching out for Moderna as it pursues diverse delivery methods and indications for its proprietary neoantigen technology.

Bullish Signals
  • Moderna is expanding its pipeline by launching a new study, Interpath-014, to test the intismeran autogene combination with subcutaneous Keytruda in adjuvant NSCLC, diversifying beyond intravenous delivery.
  • This new trial will enroll patients with earlier stage I disease, potentially opening access to this innovative therapy for a broader patient population compared to existing trials focusing on stage II-IIIB patients.
  • Moderna has two ongoing adjuvant NSCLC phase 3 trials (Interpath-002 and Interpath-009) that are already recruiting, alongside the new Interpath-014 study, providing a comprehensive portfolio approach to testing the intismeran/Keytruda combination.
  • Moderna's stock has climbed in anticipation of positive results from the upcoming phase 3 readouts, particularly for the adjuvant melanoma trial (Interpath-001), signaling investor confidence despite timing uncertainties about the 2026 data release.
Risk Factors
  • Moderna is awaiting key phase 3 data with its Merck & Co-partnered neoantigen immunotherapy intismeran autogene in adjuvant melanoma, creating uncertainty for the stock until results are confirmed.
  • A big readout for intismeran is expected in 2026 from the Interpath-001 trial in adjuvant melanoma, but Moderna has already raised doubts about the timing of the readout, suggesting potential delays or lack of confidence in the schedule.
  • The stock has climbed in anticipation of a positive result, which could lead to a disappointment-driven sell-off if the 2026 data does not meet elevated investor expectations.
  • Moderna seems to have introduced caution by saying it expects the Interpath-001 results 'potentially in 2026', which indicates possible uncertainty around the timeline and potential delays affecting investor sentiment.
Full Analysis
Moderna is expanding its clinical portfolio for its neoantigen immunotherapy, Intsmieran (autogene), as it awaits pivotal phase 3 data in adjuvant melanoma. A new study, Interpath-014, has been registered to evaluate Intsmieran combined with subcutaneous Keytruda Qlex in the adjuvant treatment of non-small cell lung cancer (NSCLC). This addition complements two existing phase 3 trials: Interpath-002, which recruits stage II-IIIB patients without prior neoadjuvant therapy, and Interpath-009, which targets those who did not fully respond to prior neoadjuvant Keytruda plus chemotherapy. A key distinction is that both Interpath-002 and Interpath-009 utilize intravenous Keytruda, whereas the new Interpath-014 study will investigate Intsmieran with or without subcutaneous Keytruda against a placebo control. Furthermore, while the existing trials focus on earlier postoperative stages (stage II-IIIB), Interpath-014 is designed to enroll patients with earlier stage I disease. The company plans to launch Interpath-014 in May, marking a strategic diversification beyond its current melanoma-focused research. Moderna has previously seen its stock appreciate ahead of anticipated positive results from the Interpath-001 trial in adjuvant melanoma. However, in its fourth-quarter press release, Moderna introduced some uncertainty regarding the specific timing of this key readout. While 2026 was initially projected as the likely year for data disclosure, Moderna now expects the Interpath-001 results "potentially in 2026," suggesting a potential shift or elongation in the expected timeline for that major milestone. This strategic move highlights Moderna's continued investment in immuno-oncology partnerships with Merck & Co to broaden the indications for Intsmieran. The comparative design of Interpath-014, specifically testing the combination versus placebo in stage I disease, offers a distinct mechanistic investigation compared to the existing head-to-head trials against Keytruda alone. Successful execution of Interpath-014 would further substantiate the efficacy of combining neoantigen therapies with checkpoint inhibitors in earlier-stage lung cancer, potentially opening new market avenues for the collaboration. The overarching goal remains to provide adjuvant options for patients who may not respond to immunotherapy monotherapy or require enhanced treatment strategies post-surgery.